Nakhanov A 1

1. Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up
2. Development of an ELISA Using Recombinant Chimeric SM Protein for Serological Detection of SARS-CoV-2 Antibodies
3. Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
4. Pre-Clinical Safety and Immunogenicity Study of a Coronavirus Protein-Based Subunit Vaccine for COVID-19
5. Complete Coding Sequence of a Lineage AY.122 SARS-CoV-2 Virus Strain Detected in Kazakhstan
6. Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters
1